Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

Despite guideline recommendations, the use of bioprosthetic heart valves has surpassed mechanical valves, but data from a large surgical database may lead to a reassessment of that practice.

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better ...

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

HYDERABAD: Doctors at Citizens Hospital successfully treated a 72-year-old patient with severe aortic valve stenosis and ...

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It ...

February is American Heart Month. Sister Bay’s David Lienau wasn’t even aware that his heart health was in jeopardy. But ...

The Heart and Vascular center at Portneuf Medical Center recently marked its 400th transaortic valve replacement procedure.

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...

Coronary events after TAVR are rare but impact survival. PCI improves outcomes, particularly in balloon-expandable valve ...

Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hrs [IST] ...